| scholarly article | Q13442814 |
| P2093 | author name string | Mark S Freedman | |
| P2860 | cites work | Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis | Q22252943 |
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 | ||
| A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis | Q34093899 | ||
| Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) | Q34375520 | ||
| Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group | Q34730962 | ||
| Multiple sclerosis: pathogenesis and treatment | Q35151851 | ||
| Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis | Q36613394 | ||
| Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years | Q36613420 | ||
| Review of teriflunomide and its potential in the treatment of multiple sclerosis | Q37235715 | ||
| Economic burden of multiple sclerosis: a systematic review of the literature | Q37733542 | ||
| Pathophysiology of multiple sclerosis and the place of teriflunomide | Q37794267 | ||
| Teriflunomide for oral therapy in multiple sclerosis | Q39504360 | ||
| Drug interactions due to cytochrome P450. | Q40562160 | ||
| Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study | Q43765361 | ||
| Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis | Q44754660 | ||
| Solving the dilemma of EEG misinterpretation | Q45800946 | ||
| Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis | Q46147015 | ||
| The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro | Q46337992 | ||
| The socioeconomic consequences of multiple sclerosis: a controlled national study | Q48298131 | ||
| A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses | Q48602930 | ||
| Randomized trial of oral teriflunomide for relapsing multiple sclerosis | Q48847857 | ||
| Socioeconomic trends in hospitalization for multiple sclerosis. | Q50550070 | ||
| Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis | Q57912405 | ||
| Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group | Q70650973 | ||
| Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone) | Q73821982 | ||
| Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group | Q77573170 | ||
| Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial | Q84204557 | ||
| P433 | issue | 5 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 192-205 | |
| P577 | publication date | 2013-09-01 | |
| P1433 | published in | Therapeutic advances in chronic disease | Q26842871 |
| P1476 | title | Teriflunomide in relapsing multiple sclerosis: therapeutic utility | |
| P478 | volume | 4 |
| Q26770664 | B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions |
| Q47868767 | Drugs approved for the treatment of multiple sclerosis: review of their safety profile. |
| Q33834110 | Effectiveness and Tolerability of Colesevelam HCl for Accelerated Elimination of Teriflunomide in Healthy Participants |
| Q39032639 | From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis |
| Q92239438 | Immunological Aspects of Approved MS Therapeutics |
| Q38534132 | Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal |
| Q92399746 | Pharmacokinetics and Bioequivalence Studies of Teriflunomide in Healthy Iranian Volunteers |
| Q26771821 | Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases |
| Q57166770 | Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children |
| Q59812455 | Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study |
| Q35280688 | Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis |
| Q90076693 | Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis |
| Q38289353 | Teriflunomide for the treatment of relapsing-remitting multiple sclerosis |
| Q26781285 | Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis |
| Q38735071 | The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review |
Search more.